| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | marinopyrrole A | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.9 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.9 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |